Educational research only—not investment advice or a recommendation. Scores and estimates may use delayed, incomplete, restated, or corrected market and filing data. Independently verify information before making an investment decision.

IDEXX Laboratories, Inc.

IDXXNASDAQ
Wall Street Score · overall investment42/100
$564.15USD+$2.90 (+0.52%)
Company website www.idexx.com
HeadquartersOne IDEXX Drive, Westbrook, ME, 04092, US
Financial statement currencyUSD · no FX conversion applied
Healthcare · Medical - Diagnostics & Research
Price updated todayFinancials updated Oct 1, 2026

IDXX · Price history

Price at last available close

$564.64

+$35.59 (+6.73%) 1M

2026-10-28

Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.

Company & revenue

About IDEXX Laboratories, Inc.

Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.

Who they are

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments.

How they make money

IDEXX Laboratories develops, manufactures, and distributes diagnostic products and services primarily for the veterinary market. The company utilizes a razor-and-blade business model, where it installs diagnostic instruments in veterinary clinics and generates recurring revenue through the ongoing sale of proprietary consumables, rapid assay test kits, and laboratory services.

Products & services

The company provides in-clinic diagnostic analyzers (chemistry, hematology, urinalysis), rapid assay test kits, diagnostic imaging systems, veterinary practice management software, and reference laboratory services.

Brands & revenue mix

IDEXX VetLab

Suite of in-clinic diagnostic analyzers.

Separate brand revenue is not available in this research.Source

IDEXX SNAP

Rapid assay test kits for point-of-care diagnostics.

Separate brand revenue is not available in this research.Source

Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.

Product / operating segments

ProductUSD 2.54B59.0%

Period ended 2025-12-31Source

ServiceUSD 1.76B41.0%

Period ended 2025-12-31Source

Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.

Geographic revenue

No reconciled geographic revenue breakdown was confirmed for the current research period.

Customer types

  • VeterinariansSource
  • Reference laboratoriesSource
  • Food and environmental testing facilitiesSource

Customer concentration

The company does not disclose significant customer concentration in its 2025 annual report.

Suppliers, materials & equipment

  • Contract manufacturing and raw material suppliers — The company relies on various third-party suppliers for components, raw materials, and contract manufacturing services; specific supplier names are not disclosed.Source

Competitors

  • Zoetis Inc. — Competes in the veterinary diagnostics and animal health market.Source
  • Heska Corporation (Mars) — Competes in veterinary diagnostic instrumentation and testing.Source

Strengths

  • Large installed base of proprietary diagnostic instrumentsSource
  • High recurring revenue from consumables and laboratory servicesSource

Risks

  • Dependence on the veterinary market and pet healthcare spendingSource
  • Intense competition in the diagnostic industrySource

Wall Street Score

Overall investment score · Quality, value, risk and opportunity

42

Weak

PoorElite

View category scores →

Company Quality

How good is the actual business—regardless of today’s stock price?

86

Strong

Financial Strength

85

Business Quality / Moat

100

Management

100

Growth Quality

38

Risk / Durability

96

Great Company · Expensive Stock

Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.

Opportunity

Opportunity Score · How does the current price compare with estimated value?

39

Avoid

Based on current valuation, company quality, recent trends, and available market signals.

View score details →

Model Outlook

12-month model · What does the model think happens next?

49/100

Building Historical Record

Model Score 49/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.

Probability unavailable — the model has not produced a calibrated probability yet.

Click for full breakdown →

WSS View

The quick read

The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.

At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.

The model outlook is currently cautious.

What we like
  • •Balance-sheet / debt profile scores strongly
  • •Recent buyback activity is present
What to watch
  • •M&A headline · Sep 30, 2026
  • •M&A headline · Sep 17, 2026
  • •M&A headline · Sep 16, 2026
  • •Valuation is a weaker part of the current profile
  • •Revenue fundamentals are weak

Company-specific research

Questions worth answering for IDXX

Research inputs 100% complete

These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.

  • •Can IDXX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • •Is IDXX's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
  • •Is IDXX's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • •What future growth or profitability would be needed to justify IDXX's current valuation?
⚠ 3 warningsView warning details
M&A headline · Sep 30, 2026M&A headline · Sep 17, 2026M&A headline · Sep 16, 2026
Business analysis: 16 days ago · Fresh

Essential Investment Snapshot

Wall Street Score

42

0–100 · Weak

Opportunity Score

39

0–100 · Weak

Market Cap

$44.44B

P/E Ratio

36.7

EPS

$14.24

52-Week High

$769.98

52-Week Low

$500.61

Beta

1.54

Intrinsic Value

$363.76

Analyst Target

$665.00

Shares Outstanding

80.7M

Total Revenue

$4.55B

Total Debt

$1.10B

Dividend

No current dividend

View dividend history

Liquidation Value / Share

$19.99

Estimated net asset value per share

Momentum & Volatility Signals

Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.

0–100 market signals
Momentum
67/ 100
+1 pts / 5d

Building upward momentum

5D +2.0% · 20D +8.1% · RSI 74 · Price vs 20D avg +4.7%
Volatility
21/ 100
-0 pts / 5d

Low movement

20D realized vol 24.9% · 60D 24.5% · Acceleration 1.02x
Momentum = Where is it going?

A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.

Volatility = How violently is it moving?

A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.

Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.

Notices for IDXX

Detected from reported data — verify before acting.

Historical repurchase activity

Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.

M&A headline · Sep 30, 2026

Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.

PRNewsWire

M&A headline · Sep 17, 2026

IDEXX Stock Gains Following the Acquisition of CoVet — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.

Zacks Investment Research

M&A headline · Sep 16, 2026

IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.

Business Wire

Community Sentiment

0 active · 0 total calls
0% Bullish (0) 0% Bearish (0)

No personal call yet on IDXX.

Potential upside factors

  • +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
  • +Large installed base of proprietary diagnostic instruments.
  • +High recurring revenue from consumables and laboratory services.
  • +Positive free cash flow may provide capacity to invest in growth.

Potential downside factors

  • −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Diagnostics & Research industry.
  • −Dependence on the veterinary market and pet healthcare spending.
  • −Intense competition in the diagnostic industry.

These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.

Create a free account to make a call.

Scores

Click any score for full breakdown
Wall Street Score
Weak42/ 100
Weak (0–50)Fair (51–71)Strong (72+)

Weak

42

Tap for breakdown →

Strong

77

Debt Cost3.6%
Debt Reduction YoY-9.1%
Debt / Equity0.67x

Tap for breakdown →

Poor

26

Revenue YoY5.8%
Revenue CAGR8.4%
Net Margin25.0%

Tap for breakdown →

Poor

19

Asset Growth YoY1.7%
Liquidation/Share$19.99
Net Assets/MCap0.06x

Tap for breakdown →

Poor

23

Earnings Yield2.8%
Buyback Yield1.8%
Debt Cost3.6%

Tap for breakdown →

Elite

100

ROIC43.3%
ROE70.7%
ROA33.1%

Tap for breakdown →

Elite

100

EPS Growth18.3%
FCF/Share Growth28.1%
Rev/Share Growth11.8%

Tap for breakdown →

Poor

10

Intrinsic Value$363.76
Value Reference$218.25
MOS-55.3%

Tap for breakdown →

Fair

58

Revenue26
Moat100
Valuation10

Tap for breakdown →

Poor

0

MOS %-55.3%
Value Reference$218.25
Deep Discount Reference$145.50

Tap for breakdown →

Poor

36

Interest Coverage35.5x
ROIC43.3%
FCF Yield2.6%

Tap for breakdown →

Poor

33

Financial36
Valuation10
Debt77

Tap for breakdown →

Fair

63

Survival Years0.5 yrs
Current Ratio1.17x
FCF Margin24.5%

Tap for breakdown →

Was this stock page easy to understand?

One click helps us improve the research experience. This is not tied to an investment decision.

Score Changes

3 historical score records available

Previous Score

41

Aug 14, 2026

Change

+0.8

points

Current Score

42

Oct 1, 2026

Category Changes

Revenue+0.3
Debt0
Assets+0.2
Capital+1.0
Management0
Moat0
Valuation+6.5
Buffett+0.8

IDXX increased 0.8 points because Valuation improved by 6.5 points.

Positive Contributors

  • + Valuation improved by 6.5 points

Projected Score

Projected Score

46

Projected Change

+4.0 points

Preliminary comparable-period financial changes suggest improvement of approximately 4.0 points. This is a projected estimate, not the official WallStreetScore.

Price vs. Value

Overvalued

Current Price

$564.15

Model Intrinsic Value

$363.76

Difference

+$200.40

+55.1% vs IV

Margin of Safety

-55.1%

UndervaluedFair ValueOvervalued
Value Reference: $218.25
Deep Discount Reference: $145.50

Financial Charts

Revenue

201420152016201720182019202020212022202320242025$0$1.5B$3.0B$4.5B$6.0B

Additional Metrics

Operating Cash Flow

201520172019202120232025$0$300M$600M$900M$1.2B

Total Debt

201520172019202120232025$0$400M$800M$1.2B$1.6B

Total Assets

201520172019202120232025$0$850M$1.7B$2.5B$3.4B

Net Margin %

No data
Monetary values in USD. Share counts in raw units.

Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.

Line ItemTTM2025202420232022202120202019201820172016
Revenue$4.55B$4.30B$3.90B$3.66B····························
Cost of Revenue$1.71B$1.64B$1.52B$1.47B····························
Gross Profit$2.84B$2.66B$2.38B$2.19B····························
Research & Development$261.5M$251.2M$219.8M$191.0M····························
SG&A Expenses$1.12B$1.05B$1.03B$901.9M····························
Operating Expenses$1.38B$1.30B$1.25B$1.09B····························
EBITDA$1.62B$1.47B$1.28B$1.22B····························
Operating Income$1.46B$1.36B$1.13B$1.10B····························
Interest Expense$39.1M$38.3M$31.2M$41.6M····························
Income Before Tax$1.42B$1.32B$1.11B$1.06B····························
Income Tax Expense$284.8M$264.7M$222.0M$216.1M····························
Net Income$1.14B$1.06B$887.9M$845.0M····························
Basic EPS$14.24$13.17$10.77$10.17····························
Basic Shares80.10M80.10M82.47M83.07M····························
Diluted Shares80.67M80.67M83.25M83.98M····························
Upgrade to Premium for up to 10 annual periods, where available.
Upgrade to Premium

Earnings Summary

Estimated earnings date:Nov 2, 2026
Estimated EPS: $3.71Estimated revenue: $1.19B
Jun 30, 2026Q2FY2026

Revenue

$1.22B

Estimate unavailable.

Revenue Beat/Miss

Not available (no estimate stored)

EPS

$4.19

Estimate unavailable.

EPS Beat/Miss

Not available (no estimate stored)

Debt Change

-11.4%

Cash Change

+19.6%

Margin Change

+1.3 pp

Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.

Financial Changes Since Prior Period

What Improved

  • Margins expanded
  • Cash position grew
  • Debt reduced

Potential Score Impact

Positive indicators included revenue growth, EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.

Stored Earnings Analysis

Revenue increased 9.7%. EPS increased 15.4%. Cash increased 19.6%. Total debt declined 11.4%. Net income margin improved by 1.3 percentage points.

Earnings-Call Transcript

Earnings-call transcript analysis is not currently available.

These results may influence future scores when the next evaluation is completed.

Upgrade to Premium to unlock all earnings history.View plans
Earnings data: 120 days ago · Stale

Insider Activity

Guru / Smart Money

Guru Score

38

Smart Money

38

Number of Gurus

3

Total Guru Value

Avg Portfolio Weight

Largest Holder

Largest Holder %

New Positions

Increased Positions

Reduced Positions

Exited Positions

Net Guru Sentiment

Loading data...

Short Interest

Government disclosed trading activity is available on the Smart Money directory. Filings may be delayed and may not represent complete current holdings.

Dividend History

Dividend data is not available yet. Missing data does not mean this company pays no dividend.

Conservative Projected Values

3 Years

$———.——

Premium

5 Years

$———.——

Premium

10 Years

$———.——

Premium

Conservative Projection Rate

——%

Premium

Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.

Conservative Projected Values

Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.

Start 7-Day Free Trial

Historical Outperformance Record

Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.

Start 7-Day Free Trial

Historical Trends

3 historical records
Jul 23, 26Aug 14, 26Oct 1, 260255075100

Historical Score Chart

3 of 3 records shown

Wall Street Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Debt Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Revenue Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Asset Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Capital Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Management Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Moat Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Valuation Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Buffett Score

Jul 23, 26Aug 14, 26Oct 1, 260255075100

Intrinsic Value

Jul 23, 26Aug 14, 26Oct 1, 26$336.00$343.00$350.00$357.00$364.00

Value Reference

Jul 23, 26Aug 14, 26Oct 1, 26$200.00$205.00$210.00$215.00$220.00

Margin of Safety %

Jul 23, 26Aug 14, 26Oct 1, 26-0.7%-0.6%-0.6%-0.5%-0.4%

Related Companies

Medical - Diagnostics & Research

BLLN

BillionToOne, Inc.

52Fair
$115.38View

MEDP

Medpace Holdings, Inc.

51Fair
$673.79View

VCYT

Veracyte, Inc.

47Weak
$48.77View

QGEN

Qiagen N.V.

43Weak
$50.17View

CDNA

CareDx, Inc

40Weak
$70.53View

A

Agilent Technologies, Inc.

40Weak
$172.12View

News

Rumor Mill · IDXX

Corporate developments & opportunities

Explore market →

No reviewed developments match this filter.

Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.

Related Stock Research

Continue researching this company with related Wall Street Score rankings and investing guides.

Highest Wall Street Score stocksBest growth stocksBest healthcare stocksHow Wall Street Score worksHow to analyze a stockUnderstanding financial healthIntrinsic value guide

Score Alerts

Premium unlocks alerts when a score rises, falls, or reaches your target price.

Start 7-Day Free Trial

Portfolio Score

Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.

Start 7-Day Free Trial